Ann S LaCasce

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Post-transplant lymphoproliferative disorders
    Ann S LaCasce
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 11:674-80. 2006
  2. pmc Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008
  3. doi request reprint Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy
    George P Canellos
    Medical Oncology Hematology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:1611-5. 2010
  4. doi request reprint Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma
    Ann S LaCasce
    Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Semin Hematol 45:85-9. 2008
  5. doi request reprint Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients
    Yi Bin Chen
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    Leuk Lymphoma 51:789-96. 2010
  6. ncbi request reprint Primary mediastinal large B-cell lymphoma
    Jason E Faris
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA
    Clin Adv Hematol Oncol 7:125-33. 2009
  7. pmc Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 143:361-8. 2008
  8. doi request reprint Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis
    Alfred Ian Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Cancer 116:3835-42. 2010
  9. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
  10. ncbi request reprint Enzastaurin
    Yi Bin Chen
    Dana Farber Cancer Institute, Massachusetts General Hospital, GRB 740, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Investig Drugs 17:939-44. 2008

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Post-transplant lymphoproliferative disorders
    Ann S LaCasce
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 11:674-80. 2006
    ..Prognosis is variable, due in part to the heterogeneity of the disease, which ranges from reactive plasmacytic hyperplasia to aggressive monoclonal disease...
  2. pmc Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network
    Ann S LaCasce
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:5107-12. 2008
    ..We sought to estimate the impact of expert review in the modern era by comparing final pathologic diagnoses at five comprehensive cancer centers with diagnoses assigned at referring centers...
  3. doi request reprint Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy
    George P Canellos
    Medical Oncology Hematology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:1611-5. 2010
    ..This study examines the impact of chemotherapy alone in treatment of limited-stage, nonbulky HL, radiation therapy eliminated from primary treatment...
  4. doi request reprint Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma
    Ann S LaCasce
    Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Semin Hematol 45:85-9. 2008
    ..Until such trials are mature, we do not recommend using these agents in combination outside of the research setting...
  5. doi request reprint Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients
    Yi Bin Chen
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    Leuk Lymphoma 51:789-96. 2010
    ..In conclusion, patients who fail R-CHOP appear to benefit from ASCT, but they may have a worse prognosis compared to patients who fail CHOP alone...
  6. ncbi request reprint Primary mediastinal large B-cell lymphoma
    Jason E Faris
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02115, USA
    Clin Adv Hematol Oncol 7:125-33. 2009
    ....
  7. pmc Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 143:361-8. 2008
    ..026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden...
  8. doi request reprint Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis
    Alfred Ian Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02114, USA
    Cancer 116:3835-42. 2010
    ..The majority of patients with Hodgkin lymphoma (HL) achieve disease remission after primary therapy. To the best of the authors' knowledge, no consensus exists for postremission surveillance imaging...
  9. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  10. ncbi request reprint Enzastaurin
    Yi Bin Chen
    Dana Farber Cancer Institute, Massachusetts General Hospital, GRB 740, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Investig Drugs 17:939-44. 2008
    ..Enzastaurin is a novel antineoplastic and antiangiogenic agent that acts through inhibition of protein kinase C (PKC)...
  11. doi request reprint Nodular lymphocyte predominant Hodgkin lymphoma
    Alfred Ian Lee
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Oncologist 14:739-51. 2009
    ..For relapsed disease, treatment options include the salvage therapies used in classical HL, and rituximab...
  12. doi request reprint Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database
    Michelle E Kho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:3209-12. 2008
    ..Clinical trials and outcomes studies often rely on nonphysicians to abstract complex data from medical records, but the reliability of these data are rarely assessed...
  13. ncbi request reprint Lymphoma: risk and response after solid organ transplant
    Caron A Jacobson
    Division of Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 24:936-44. 2010
    ..Further clinical investigation, including randomized controlled trials, will be important in reaching this goal...
  14. ncbi request reprint Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  15. ncbi request reprint Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology
    Andrew D Zelenetz
    J Natl Compr Canc Netw 4:258-310. 2006